latest news on glp 1 Fmr. FDA Commissioner weighs in Medicare's involvement in GLP-1 prices Half of GLP-1 users ditch

When a new prescription drug enters the market, the question for employers isnt just does it work? Its what does covering it mean for our people, our plan, and our longterm costs? That question became especially relevant in early 2026, when an oral version of Wegovy entered the market with widespread media coverage

The GLP-1 vitamin guide provides a framework for identifying and addressing the most common deficiencies

doi: 10.1001/jama.2022.0078 76 US National Institutes of Health

Many patients begin noticing reduced hunger within the first few weeks, with visible weight changes developing progressively over several months

Off-label use for women who have gained 10-20 lbs during menopause, or for people at a normal body weight who want it for the brain/heart/kidney protective effects, is a much harder situation

If you are comparing your options across the full GLP-1 landscape, the semaglutide vs tirzepatide comparison provides context for both injectable and oral formats